Dawn Allen, an executive from Tate & Lyle, will assume the role of Chief Financial Officer at consumer healthcare firm Haleon starting November 1, 2024. She replaces Tobias Hestler, who is stepping down due to health reasons.
Hestler will remain with the company until the year-end to facilitate a seamless transition after stepping down from the board on November 1, 2024.
Brian McNamara, CEO of Haleon, expressed confidence in Allen’s abilities, citing her extensive experience in finance and consumer sectors as valuable additions to the executive team. He also acknowledged Hestler’s contributions in shaping Haleon as a standalone business and thanked him for his partnership over the years.
Dawn Allen brings a wealth of experience to her new role, currently serving as the finance chief at Tate & Lyle plc. Prior to her tenure at Tate & Lyle, she spent 25 years at Mars Inc., holding various leadership positions including Global CFO and VP of Global Transformation. Her career also includes senior financial roles in Europe and the US.
In addition to her new role at Haleon, Allen serves as a non-executive director and member of the audit and risk committee at ITV plc.
Haleon is a global consumer health company that provides vitamins, minerals, supplements (VMS), and oral health products. Their brands include Sensodyne, Panadol, Advil, Voltaren, Theraflu, Otrivin, and Centrum
